Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...
Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in a legal tussle with Sandoz over the patent covering the blockbuster inflammatory diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback